Galvanize Therapeutics reports a $136.2M equity raise from 26 investors, including $130M in new money; no broker listed
- Form type
- Form D (new notice) Reg D Rule 506(b)
- Amount
- $136,185,232 sold to 26 investors; offering fully sold
- Investors
- 26
- First sale
- Nov 6, 2026
- Filed
- Nov 18, 2026, 2:02 PM ET
Galvanize Therapeutics, Inc., a Redwood City, California biotechnology company formerly known as Gala Therapeutics, filed a new Form D on Wednesday reporting a fully sold $136.2 million equity offering to 26 investors. The filing says about $130.0 million is new money and $6.2 million came from converting debt. The first sale was on Nov. 6, and no broker or sales compensation is listed.
What to watch
- $136.2M equity offering, fully sold to 26 investors
- About $130.0M new money and $6.2M debt conversion, per the filing
- First sale Nov. 6, 2026; Rule 506(b)
- No broker or sales compensation listed
- Company previously filed as Gala Therapeutics and has earlier Form Ds from 2019, 2022 and 2025
Market context
The filing comes on a mixed day for U.S. stocks, with the S&P 500 down 0.2% for a fifth straight loss, the Dow off 1.1% and the Nasdaq up 0.4%.
Opens the filing on disclosurequest.com
Share this filing
https://www.crowdfundinsider.com/filings/galvanize-therapeutics-raises-136m-reg-d/